Literature DB >> 14648340

Antibody response to influenza A vaccination in children with nephrotic syndrome.

Hakan M Poyrazoğlu1, Ruhan Düşünsel, Zübeyde Gündüz, Türkan Patiroğlu, Selmin Köklü.   

Abstract

The aim of this study was to determine the antibody response to influenza vaccination in children with nephrotic syndrome (NS). Nineteen children with NS and 10 healthy controls were vaccinated with a 1999-2000 influenza vaccine. A dose of 0.25 ml was used for those under 6 years and 0.5 ml for those over 6 years. All children were given two doses with a month between each dose. Antibody titers were measured before vaccination and 1 month after vaccination in both groups and 6 months after vaccination in 8 patients with NS. The proportion of subjects in the nephrotic group with protective antibody titers before immunization (10.5%) was significantly lower than the proportion at 1 (78.9%) and 6 months (87.5%) post vaccination. The mean concentration of specific IgG antibodies to influenza A in the NS group increased 6-fold at 1 month and approximately 14-fold at 6 months. These results suggest that pediatric patients with NS have an adequate antibody response to influenza A vaccine. Protective antibody titers to influenza A were maintained at 6 months after immunization in 8 patients with NS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648340     DOI: 10.1007/s00467-003-1301-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

1.  Nephrotic syndrome following hepatitis B vaccination.

Authors:  I Işlek; K Cengiz; M Cakir; S Küçüködük
Journal:  Pediatr Nephrol       Date:  2000-01       Impact factor: 3.714

2.  Effect of immunomodulator thymopentin on impaired seroresponse to influenza vaccine in patients on haemodialysis.

Authors:  W E Beyer; T C Noordzij; P Kramer; P P Diderich; C T Op den Hoek; J Janssen; N Masurel; W Weimar
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Influenza antibody titers after vaccination of chronic renal failure patients; before and during hemodialysis, or on continuous ambulatory peritoneal dialysis.

Authors:  T Suga; H Niki; M Niikura; Y Matsumoto; T Nishimura; K Nakajima; M Miyazaki; M Endoh; Y Nomoto; H Sakai
Journal:  Tokai J Exp Clin Med       Date:  1990-05

Review 4.  The immune system in minimal change nephrotic syndrome.

Authors:  H W Schnaper
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

5.  Current status of vaccines and immune globulins for children with renal disease.

Authors:  R W Steele
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

6.  Impaired humoral and cell-mediated immune responses in dialyzed patients after influenza vaccination.

Authors:  R Cappel; D Van Beers; C Liesnard; M Dratwa
Journal:  Nephron       Date:  1983       Impact factor: 2.847

Review 7.  Humoral immune response to influenza vaccination in patients from high risk groups.

Authors:  L B Brydak; M Machala
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

8.  Hemagglutination-inhibiting antibodies in vaccinated children with renal disease.

Authors:  K J Sheth; G V Sedmak; M E Freeman; C Eisenberg
Journal:  JAMA       Date:  1979-10-19       Impact factor: 56.272

9.  Influenza A in immunocompromised patients.

Authors:  P Ljungman; J Andersson; J Aschan; L Barkholt; A Ehrnst; M Johansson; O Weiland
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

Review 10.  Immunization guidelines for pediatric renal disease.

Authors:  B A Fivush; A M Neu
Journal:  Semin Nephrol       Date:  1998-05       Impact factor: 5.299

View more
  7 in total

1.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.

Authors:  Yoshitsugu Kaku; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Kenji Ishikura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.801

2.  Benign acute childhood myositis complicating influenza B infection in a boy with idiopathic nephrotic syndrome.

Authors:  Piotr Skrzypczyk; Joanna Przychodzień; Małgorzata Pańczyk-Tomaszewska
Journal:  Cent Eur J Immunol       Date:  2016-10-25       Impact factor: 2.085

3.  Influenza virus vaccination in pediatric nephrotic syndrome significantly reduces rate of relapse and influenza virus infection as assessed in a nationwide survey.

Authors:  Shingo Ishimori; Takashi Ando; Kaori Kikunaga; Chikako Terano; Mai Sato; Fumiyo Komaki; Riku Hamada; Yuko Hamasaki; Yoshinori Araki; Yoshimitsu Gotoh; Koichi Nakanishi; Hitoshi Nakazato; Takeshi Matsuyama; Kazumoto Iijima; Norishige Yoshikawa; Shuichi Ito; Masataka Honda; Kenji Ishikura
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

4.  Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.

Authors:  Koichi Kamei; Masao Ogura; Mai Sato; Kentaro Nishi; Kensuke Shoji; Takanori Funaki; Chikara Ogimi; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2022-08-01       Impact factor: 3.651

5.  Vaccinations in children on immunosuppressive medications for renal disease.

Authors:  Sushmita Banerjee; Pathum Vindana Dissanayake; Asiri Samantha Abeyagunawardena
Journal:  Pediatr Nephrol       Date:  2015-10-08       Impact factor: 3.651

Review 6.  The non-immunosuppressive management of childhood nephrotic syndrome.

Authors:  James McCaffrey; Rachel Lennon; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2015-11-10       Impact factor: 3.714

7.  Influenza virus vaccination in children with nephrotic syndrome: insignificant risk of relapse.

Authors:  Shingo Ishimori; Koichi Kamei; Takashi Ando; Takahisa Yoshikawa; Yuji Kano; Hiroko Nagata; Ken Saida; Mai Sato; Masao Ogura; Shuichi Ito; Kenji Ishikura
Journal:  Clin Exp Nephrol       Date:  2020-07-27       Impact factor: 2.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.